Worth reading
64In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Neutral
Direction inferred from the company’s description.Scale
31733101
SharesWording
Conditional
How definitive the wording is.This transaction
This tender offerCounterpartyTAKARA HOLDINGS INC.
Disclosing companyTAKARA BIO INC.
The voting-rights ratio is the share of the votes exercisable at a shareholders’ meeting that will be held after this transaction.
TimelineThe spacing between the points is proportional to the actual number of days.
Consideration and expenses
Type of ConsiderationCash
Tender offer price¥1,150 per common share
Minimum number of shares to be purchased6,927,000 shares
Tender offer periodFrom 16 February 2026 to 6 April 2026 (34 business days)
Procedures and assumptions
Conditions Precedent to ExecutionThis squeeze-out procedure and the prescribed procedures
Management structure after acquisitionThe tender offeror plans to carry out this squeeze-out procedure to make the tender offeror the sole shareholder of the target company. Following completion of the procedure, the target company's shares are expected to be delisted.
| Item | Details |
|---|---|
| Transaction name | This tender offer |
| Counterparty name | TAKARA HOLDINGS INC. |
| Name of the Subject Company | TAKARA BIO INC. |
| Type of Consideration | Cash |
| Tender offer price | ¥1,150 per common share |
| Minimum number of shares to be purchased | 6,927,000 shares |
| Tender offer period | From 16 February 2026 to 6 April 2026 (34 business days) |
| Number of shares acquired | 31,733,101 shares, equivalent to 317,331 voting rights |
| Voting rights ownership percentage | Before 60.91% → after 87.27% |
| Date of board resolution | 13 February 2026 |
| Execution Date / Effective Date | 13 April 2026 (settlement commencement date) |
| Conditions Precedent to Execution | This squeeze-out procedure and the prescribed procedures |
| Management structure after acquisition | The tender offeror plans to carry out this squeeze-out procedure to make the tender offeror the sole shareholder of the target company. Following completion of the procedure, the target company's shares are expected to be delisted. |
Items this document does not state (19)
Business Description of the Subject CompanyLocation of the Subject CompanyCapital Stock of the Subject CompanyDate of Establishment of the Subject CompanyNet Sales of the Subject CompanyOperating Profit of the Subject CompanyNet Income of the Subject CompanyNet Assets of the Subject CompanyAcquisition priceExpenses other than the acquisition priceMerger ratio/share exchange ratioFunding arrangementsGoodwill amountAmount of extraordinary income (loss)Impact on Business PerformanceContract DateValuation methodologyIndependent valuation institutionSpecial Committee
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company states that its policy and outlook following the tender offer remain unchanged from the details announced at the commencement of the tender offer on 13 February 2026.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.